Last reviewed · How we verify
Autologous CD19-targeting CAR T cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Autologous CD19-targeting CAR T cells (Autologous CD19-targeting CAR T cells) — Hebei Senlang Biotechnology Inc., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Autologous CD19-targeting CAR T cells TARGET | Autologous CD19-targeting CAR T cells | Hebei Senlang Biotechnology Inc., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Autologous CD19-targeting CAR T cells CI watch — RSS
- Autologous CD19-targeting CAR T cells CI watch — Atom
- Autologous CD19-targeting CAR T cells CI watch — JSON
- Autologous CD19-targeting CAR T cells alone — RSS
Cite this brief
Drug Landscape (2026). Autologous CD19-targeting CAR T cells — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-cd19-targeting-car-t-cells. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab